Method of treating rheumatoid arthritis with an anti-IL-6R antibody
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
1. A method for reducing a symptom of rheumatoid arthritis (RA) in a subject, comprising:
administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof which specifically binds to human interleukin-6-receptor (hIL-6R) with a K D of about 500 pM or less as measured by surface plasmon resonance,
wherein the antibody or antigen-binding fragment comprises a complementarity determining region (CDR) sequence combination of SEQ ID NOs:21/23/25/29/31/33.
2. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a HCVR/LCVR pair of SEQ ID NO: 19/27.
3. The method of claim 1 , wherein the antibody or antigen-binding fragment specifically binds to human interleukin-6 (hIL-6R) with a K D of about 300 pM or less as measured b surface s plasmon resonance.
4. The method of claim 1 , wherein the antibody or antigen-binding fragment specifically binds to human interleukin-6 (hIL-6R) with a K D of about 200 pM or less as measured by surface plasmon resonance.
5. The method of claim 1 , wherein the antibody or antigen-binding fragment specifically binds to human interleukin-6 (hIL-6R) with a K D of about 100 pM or less as measured by surface plasmon resonance.
6. The method of claim 5 , further comprising:
a second therapeutic agent selected from the group consisting of: methotrexate; sulfasalazine; hydroxychloroquine; leflunomide; etanercept; infliximab; adalimumab; golimumab; rilonacept; anakinra; abatacept; cetiolizumab; and rituximab.
7. The method of claim 1 , wherein the therapeutically effective amount of the antibody or antigen-binding fragment is about 50 mg to about 200 mg.
8. A method for reducing a symptom of rheumatoid arthritis in a subject, the method comprising:
(a) administering to the subject a first dose of a human antibody or antigen-binding fragment thereof which specifically binds to human interleukin-6 receptor (hIL6-R) with a K D of about 500 pM or less as measured by surface plasmon resonance, and
(b) administering to the subject at least one subsequent dose of the human antibody or antigen-binding fragment,
wherein the antibody or antigen-binding fragment comprises a complementarity determining region (CDR) sequence combination of SEQ ID NOs:21/23/25/29/31/33.
9. The method of claim 8 , wherein the human antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) and light chain variable region (LCVR) pair (HCVR/LCVR) of SEQ ID NO: 19/27.
10. The method of claim 8 , wherein the first dose and the subsequent dose are each about 50 mg to about 200 mg of the human antibody or antigen-binding fragment.
11. The method of claim 8 , wherein the first dose and the subsequent dose are administered 1 week to 6 weeks apart.
12. The method of claim 10 , wherein the first dose and the subsequent dose are each 50 mg, 100 mg, 150 mg or 200 mg and administered 1 week apart or 2 weeks apart.
13. The method of claim 12 , further comprising administering to the subject one or more subsequent doses of the human antibody or antigen-binding fragment at 50 mg, 100 mg, 150 mg, or 200 mg, weekly or biweekly.
14. The method of claim 8 , further comprising administering a second therapeutic agent to the subject.